183133-94-0 Usage
Description
Cabazitaxel is a kind of Second line Drug for the treatment of prostate cancer, FDA Priority Review status approval listing is obtained because its curative effect is remarkable, for the advanced prostate cancer patients to the invalid even aggravation of Docetaxel, the first-selected medicine being used for the treatment of late period, hormone antagonist type prostate cancer.7,10-dimethoxy-10-Dab III is the important intermediate preparing Cabazitaxel.
Uses
4-Deacetyl-4-propionyl Cabazitaxel is an impurity of Cabazitaxel (C046500).A novel semi-synthetic taxane with antitumor activity used for the treatment of castration-resistant prostate cancer. A microtubule inhibitor.
Synthesis
Solvent is methylene dichloride, and alkali is the two dimethylamino naphthalene of 1,8-, and the mol ratio of 10-deacetylate Bakating III and trimethylammonium oxygen Tetrafluoroboric acid is 1:35; The mol ratio of 10-deacetylate Bakating III and alkali is 1:45;By 10-Dab (10g, 18.4mmol) be dissolved in methylene dichloride (200ml), add 1, the two dimethylamino naphthalene (177.2g of 8-, 828mmol), stirring at room temperature half an hour, add trimethylammonium oxygen Tetrafluoroboric acid (95.2g, 643.4mmol) again, stirring at room temperature 20h, suction filtration reaction solution, filter cake methylene dichloride washes 3 times, collects filtrate, and after concentrated, column chromatography (chloroform: methyl alcohol=100:3) obtains 7,10-dimethoxy-10Dab III 4.6g, yield 43.7%.
Check Digit Verification of cas no
The CAS Registry Mumber 183133-94-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,1,3 and 3 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 183133-94:
(8*1)+(7*8)+(6*3)+(5*1)+(4*3)+(3*3)+(2*9)+(1*4)=130
130 % 10 = 0
So 183133-94-0 is a valid CAS Registry Number.
InChI:InChI=1S/C31H40O10/c1-16-19(33)14-31(36)26(40-27(35)18-11-9-8-10-12-18)24-29(5,25(34)23(38-7)22(16)28(31,3)4)20(37-6)13-21-30(24,15-39-21)41-17(2)32/h8-12,19-21,23-24,26,33,36H,13-15H2,1-7H3/t19-,20-,21+,23+,24?,26-,29+,30-,31+/m0/s1
183133-94-0Relevant articles and documents
Isolation, identification and characterization of potential impurities in cabazitaxel and their formation
Wang, Yongyi,Feng, Feng,Chen, Lei,Zhao, Hongtao,Tian, Lianzhong
, p. 783 - 788 (2014)
-
Cabazitaxel precursor derivative as well as synthesis method and application thereof
-
Paragraph 0079, (2020/02/20)
The invention discloses a preparation method of 7,10-dimethoxy-10-DAB (deacetyl baccatin) and a cabazitaxel precursor derivative as well as a synthesis method and application of the cabazitaxel precursor derivative. The synthesis method disclosed by the invention has the advantages of being easy in raw material obtaining, less in step, simple and convenient in purification and high in yield, and has the prospect of industrial production. The cabazitaxel precursor derivative synthetisedby the synthesis methoddisclosed by the invention has excellent antitumor activity and great application prospects.
Preparation method of 7beta,10beta-dimethoxy-10-deacetylbaccatin III
-
Paragraph 0036; 0046; 0047, (2017/08/29)
The invention relates to a preparation method of 7beta,10beta-dimethoxy-10-deacetylbaccatin III. Particularly, the method provided by the invention takes acetylbaccatin as a raw material and comprises a series of the following steps: protecting through silicon protecting groups at a 7 site and a 13 site; selectively removing the silicon protecting group at the 7 site; directly alkylating at the 7 site and a 10 site; and finally, removing the silicon protecting group at the 13 site to prepare a taxane compound, namely the 7beta,10beta-dimethoxy-10-deacetylbaccatin III shown as a formula V. (The formula V is shown in the description.).